--- title: "Cut the Hype: What's Really Happening in Hong Kong's Fringe Markets" type: "News" locale: "en" url: "https://longbridge.com/en/news/296207148.md" description: "From Star Plus Legend's robot rumors to Kintor's licensing deals, the fringe of the HK market is full of empty promises and shrinking profits. Beware of the micro-cap illusion." datetime: "2026-08-18T09:43:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296207148.md) - [en](https://longbridge.com/en/news/296207148.md) - [zh-HK](https://longbridge.com/zh-HK/news/296207148.md) generator: "portal-rs" --- # Cut the Hype: What's Really Happening in Hong Kong's Fringe Markets I’ve been around long enough to know when someone is trying to sell me a bridge. If you look at the recent moves in some of Hong Kong’s more obscure equities, it’s a masterclass in trying to make boring or struggling businesses sound like the next big thing. Let’s be real for a second: when Star Plus Legend (6683.HK)—a company historically known for hawking bulletproof coffee and Jay Chou merchandise—sees a massive share spike on rumors of an AI robot IPO tie-up, you know the market is desperate for a narrative. IP meets robotics? Give me a break. It's pure, unfiltered speculation. Then we have the biotech hopefuls, endlessly peddling the promise of "tomorrow." Immunotech Biopharm (6658.HK) is still hyping its EAL clinical trials for liver cancer, while Kintor Pharma (9939.HK) is busy trumpeting its recent distribution deals in Korea for its hair loss ingredients. Good for them. But it’s 2026, and investors are thoroughly exhausted by science projects. The market wants to see actual commercial viability, not just another PowerPoint presentation about future pipelines. If tech and biotech are selling dreams, the traditional sectors are serving up a harsh dose of reality. Pacific Millennium Packaging (2562.HK) is bleeding margins with declining profits, and legacy catering operators like Café de Coral (0341.HK) are just trying to keep the lights on amid a challenging consumer environment. Don't even get me started on Weizhixiang (9887.HK), where the bottom line continues to slide aggressively. Some players are just opting for a disguise. China Financial Leasing (2312.HK) recently rebranded itself as LONG Investment Group—because apparently, slapping "Long" on the door will magically fix the fundamentals. Meanwhile, precision metal maker KFM Kingdom (3519.HK) and a handful of other marginal entities operating in obscure retail and basic services are doing little more than taking up space on the exchange. Here’s the deal: beware of micro-caps trying to dress themselves up as "new retail" or "AI innovators." When the tide finally goes out, we’re going to see exactly who’s swimming naked in this market. And spoiler alert: a lot of these guys don't even own a swimsuit. ### Related Stocks - [06658.HK](https://longbridge.com/en/quote/06658.HK.md) - [06603.HK](https://longbridge.com/en/quote/06603.HK.md) - [06683.HK](https://longbridge.com/en/quote/06683.HK.md) - [02562.HK](https://longbridge.com/en/quote/02562.HK.md) - [02526.HK](https://longbridge.com/en/quote/02526.HK.md) - [02312.HK](https://longbridge.com/en/quote/02312.HK.md) - [09939.HK](https://longbridge.com/en/quote/09939.HK.md) - [09887.HK](https://longbridge.com/en/quote/09887.HK.md) ## Related News & Research - [Kintor Pharma completes 52-week human safety trial of skin-whitening ingredient KT-939](https://longbridge.com/en/news/298141186.md) - [CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES , INNOVENT BIO and LEADS BIOLABS-B](https://longbridge.com/en/news/297994035.md) - [Kintor Moves to Resolve Going-Concern Audit Issue With KX-826 Commercial Push](https://longbridge.com/en/news/294548832.md) - [HSI Closes Midday at 25,345, Down 67 pts; HSTI Closes Midday at 4,477, Down 49 pts; CMOC Up over 6%; SWIRE PACIFIC A Hit New Highs](https://longbridge.com/en/news/298260064.md) - [Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NEC](https://longbridge.com/en/news/296590195.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**